Article info
PDFBiomarker studies
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
- Correspondence to Dr Thierry Dervieux; tdervieux{at}exagen.com Dr Daniel Wallace; danielwallac@gmail.com
Citation
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
Publication history
- Received September 22, 2015
- Revision received November 19, 2015
- Accepted December 8, 2015
- First published February 1, 2016.
Online issue publication
May 01, 2020
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online tables
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/